A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination with Itraconazole in Healthy Participants

Exclusion Criteria

• - History of any clinically important disease or disorder which, in the opinion of the principal investigator (PI), may either put the participant at risk because of participation in the study, or influence the results or the participant’s ability to participate in the study.
• - History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - History of drug-related hepatic toxicity.
• - Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
• - History of any treatment with QT prolongation drugs.
• - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to baxdrostat or itraconazole.
• - Participants who have previously received baxdrostat.